Gastroesophageal Junction Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

695 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 228
Recruiting: 123
Ph III recruiting: 18
Growth YoY: +39.5%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (82)

clinicaltrialsPublishedShowing 151–200 of 319 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06667050	CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer	active not recruiting	Phase 2	58	West China HospitalOTHER	1	Oct 31, 2024	clinicaltrials
NCT06666166	SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer	not yet recruiting	Phase 2	28	Yunpeng LiuOTHER	1	Oct 30, 2024	clinicaltrials